CareDx Inc
$ 23.66
0.85%
11 Jun - close price
- Market Cap 1,192,042,000 USD
- Current Price $ 23.66
- High / Low $ 24.13 / 22.88
- Stock P/E N/A
- Book Value 6.12
- EPS -0.16
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.02 %
- 52 Week High 24.13
- 52 Week Low 10.96
About
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$25.80
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-24 | 2025-11-04 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-04 | 2024-07-31 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 |
| Reported EPS | 0.34 | 0.12 | 0.28 | 0.1 | 0.1 | 0.18 | 0.14 | 0.25 | -0.03 | -0.17 | -0.18 | -0.18 |
| Estimated EPS | 0.13 | -0.01 | 0.14 | 0.12 | 0.07 | 0.1475 | 0.01 | -0.14 | -0.21 | -0.27 | -0.4 | -0.31 |
| Surprise | 0.21 | 0.13 | 0.14 | -0.02 | 0.03 | 0.0325 | 0.13 | 0.39 | 0.18 | 0.1 | 0.22 | 0.13 |
| Surprise Percentage | 161.5385% | 1300% | 100% | -16.6667% | 42.8571% | 22.0339% | 1300% | 278.5714% | 85.7143% | 37.037% | 55% | 41.9355% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDNA
2026-06-12 02:08:47
Caredx Inc (CDNA) stock recently hit a 52-week high of $24.04, reflecting significant growth with a 26.23% increase over the past year and a 24.52% year-to-date return. Despite its market capitalization of $1.23 billion and 19.17% revenue growth, InvestingPro analysis suggests the stock may be overvalued, advising investor caution. The company also reported strong Q1 2026 financial results, beating EPS and revenue forecasts, and announced the strategic acquisition of Naveris for up to $260 million.
2026-06-11 20:09:50
John Hanna, an insider at CareDx, Inc. (CDNA), has filed a Form 144 to report proposed dispositions of common stock. The filing details an exercise of stock options for 29,294 shares and restricted stock units for 10,887 shares, alongside recent 10b5-1 sales of 4,835 shares and 10,282 shares with specified dollar proceeds. These transactions are described as procedural, involving scheduled rule-based sales rather than discretionary open-market actions.
2026-06-10 04:24:00
This article analyzes Caredx Inc. (NASDAQ: CDNA), highlighting a near-term neutral sentiment amidst mid and long-term strength. It reports an exceptional 50.4:1 risk-reward short setup, targeting 14.5% downside with minimal risk. The article details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
2026-06-09 20:09:29
CareDx, Inc. reported that its Secretary and General Counsel, Jeffrey Adam Novack, had 1,292 shares of common stock withheld by the company to cover tax obligations stemming from the vesting of restricted stock units (RSUs). The shares were valued at $21.95 each for this tax-withholding disposition. After the transaction, Novack directly holds 112,632 shares of CareDx common stock.
2026-06-09 14:09:29
CareDx (CDNA) has seen choppy trading recently but shows improvement over the past quarter and year. The stock is considered 15% undervalued with a fair value of $25.80, driven by the potential of AI-driven diagnostics like AlloSure Plus. However, potential reimbursement changes and increased regulatory scrutiny pose risks to this valuation.
2026-06-09 13:40:05
CareDx, Inc. presented at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The analyst, Elizabeth Koslosky, Head of the Life Science Tools and Diagnostics team at Goldman Sachs, introduced the presentation. Access to the full article content is restricted to subscribers.
